Berasain Carmen, Elizalde María, Urtasun Raquel, Castillo Josefa, García-Irigoyen Oihane, Uriarte Iker, Latasa Maria U, Prieto Jesús, Avila Matías A
Division of Hepatology & Gene Therapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, CIMA, Avda, Pio XII, n55, 31008 Pamplona, Spain.
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Hepat Oncol. 2014 Apr;1(2):241-252. doi: 10.2217/hep.13.17. Epub 2014 Mar 20.
Hepatocellular carcinoma (HCC) is a molecularly complex tumor that is resistant to standard and targeted therapies, and thus a deadly disease. In this context, the identification of key alterations driving HCC development is therefore essential. The implementation of next-generation sequencing techniques has underscored earlier realizations of the marked dysregulation of pre-mRNA splicing in HCC. Impairments in alternative splicing may lead to the expression of protumorigenic protein isoforms and to the generation of unstable mRNA species. Mechanistically, mutations in key nucleotides are responsible for many of these alterations in different types of tumors. However, changes in the expression of factors involved in the regulation of the splicing machinery are also important determinants in the derangement of pre-mRNA splicing. Here we discuss recent reports on the alteration of splicing factors in HCC, the pathological significance of these changes, and the identification of cell signaling pathways leading to the missplicing of genes in hepatocarcinogenesis.
肝细胞癌(HCC)是一种分子结构复杂的肿瘤,对标准疗法和靶向疗法均具有抗性,因此是一种致命疾病。在此背景下,识别驱动HCC发展的关键改变至关重要。下一代测序技术的应用进一步证实了此前关于HCC中前体mRNA剪接显著失调的认识。可变剪接受损可能导致促肿瘤蛋白异构体的表达以及不稳定mRNA种类的产生。从机制上讲,关键核苷酸的突变是不同类型肿瘤中许多此类改变的原因。然而,参与剪接机制调控的因子表达变化也是前体mRNA剪接紊乱的重要决定因素。在此,我们讨论了近期关于HCC中剪接因子改变的报道、这些变化的病理意义,以及在肝癌发生过程中导致基因错配剪接的细胞信号通路的识别。